Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Minnesota Community-Based Cognitive Training in Early Psychosis

NCT03079024
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions
Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 4 Interventional Results available

Antipsychotic Effects on Brain Function in Schizophrenia

NCT01913327
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Aripiprazole, Risperidone, Modafinil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Family-Directed Cognitive Adaptation Program
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Jamaica Plain, Massachusetts
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Cognitive-Behavior Therapy, Standard Psychiatric Treatment
Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Schizophrenia
Interventions
Valacyclovir HCI 500 mg tablets, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Bellflower, California • Los Angeles, California • Riverside, California + 9 more
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder, Psychotic Disorder NOS
Interventions
Integrated Treatment, Community Care
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
33
States / cities
San Fernando, California • Santa Clarita, California • Denver, Colorado + 30 more
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Brain Circuits in Schizophrenia and Smoking

NCT01425684
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
12 Years to 80 Years
Enrollment
837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive training, Aerobic Exercise Program, Moderated Online Social Therapy (MOST), Chorus Participatory Text Messaging Program, Healthy Living Group (HLG)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Results available

Omega-3 Dietary Supplements in Schizophrenia

NCT01786239
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
Interventions
Risperidone, Omega-3 capsules, Placebo
Drug
Lead sponsor
Delbert Robinson
Other
Eligibility
15 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Case management and supportive psychotherapy, Family psychoeducation, Cognitive training, Aerobic exercise
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Clonazepam, Placebo
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive Training, Aerobic Exercise, Case management and supportive psychotherapy, Individual Placement and Support
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Study Oxytocin - Behavioral

NCT02567032
Conditions
Schizophrenia, Oxytocin, Social Cognition, Psychotic Disorders
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
2
States / cities
San Francisco, California
Terminated Phase 4 Interventional Results available

Optimizing Response in Psychosis Study

NCT00314327
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Brooklyn, New York • Glen Oaks, New York
Conditions
Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
Interventions
BXCL501 80 Micrograms, Placebo Film, BXCL501 120 Micrograms, BXCL501 60 Micrograms
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
10 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Anaheim, California • Hialeah, Florida • Atlanta, Georgia + 2 more
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more